MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.
暂无分享,去创建一个
Galina Selivanova | Martin Enge | S. Jackson | G. Selivanova | E. Hedström | Wenjie Bao | A. Moumen | Stephen P Jackson | Abdeladim Moumen | Martin Enge | Wenjie Bao | Elisabeth Hedström | M. Enge | S. Jackson
[1] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[2] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[3] Lilya V. Matyunina,et al. Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas , 2007, PloS one.
[4] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[6] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[7] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[9] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[10] P. Farnham,et al. c-Myc target gene specificity is determined by a post-DNAbinding mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] Xin Lu,et al. ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.
[12] P. Park,et al. Discovering statistically significant pathways in expression profiling studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[13] Ronen Marmorstein,et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.
[14] Xinbin Chen,et al. MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* , 2004, Journal of Biological Chemistry.
[15] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[16] Lee Baker,et al. Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.
[17] Mengjia Tang,et al. Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.
[18] Stephen P. Jackson,et al. hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage , 2005, Cell.
[19] A. Gartel,et al. The Role of the Cyclin-dependent Kinase Inhibitor p 21 in Apoptosis 1 , 2002 .
[20] René Bernards,et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.
[21] M. Miura,et al. Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP , 1998, Oncogene.
[22] Yi Tang,et al. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.
[23] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[24] I. Simon,et al. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. , 2008, Cancer research.
[25] D. Johnson,et al. p21WAF1 Prevents Down-modulation of the Apoptotic Inhibitor Protein c-IAP1 and Inhibits Leukemic Apoptosis , 2000, Molecular medicine.
[26] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[27] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[28] Z. Weng,et al. A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.
[29] F. McCormick,et al. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines , 2008, Oncogene.
[30] A. Barsotti,et al. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner , 2008, Cell cycle.
[31] Pankaj Oberoi,et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.
[32] M. Dai,et al. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation , 2003, The EMBO journal.
[33] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[34] M. Rolfe,et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] Owen J. Marshall. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR , 2004, Bioinform..
[36] John N Weinstein,et al. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. , 2005, Cancer research.
[37] M. El-Gewely,et al. P53-responsive genes and the potential for cancer diagnostics and therapeutics development. , 2001, Biotechnology annual review.
[38] Giulia Piaggio,et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.